Sinphar Pharmaceutical Co. Ltd.
Sinphar Pharmaceutical Co. Ltd. (TAI: 1734) is trading at NT$31.95, about ₹96 at today's TWD/INR rate, as of 1 Oct 2026, 1:23 AM ET, down 0.47% today. Sinphar Pharmaceutical is not currently available to trade on Paasa; this page shows its price, statistics and the Indian tax treatment for information.
Quote
Today's low
NT$31.80
Today's high
NT$32.00
52 week low
NT$26.52
52 week high
NT$32.80
1734 opened at NT$31.85, closed previously at NT$32.10, and has traded between NT$26.52 and NT$32.80 over the past 52 weeks.
About
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and other products; and healthy food under the Sinphar, DailyCare, Migus, YouBest, and SynCoreBio brands. It also provides moisturizer repair essence, anti aging cream, renewable oi, and UV defence cream under the DYNASKIN brand; serum, revitalizing cream, hygiene, sunblock, sunscreen, and lightening tables under the Yestuner brand; and shower gel and hair shampoo. In addition, the company is involved in the provision of testing and development, as well as product design and manufacturing services. The company was incorporated in 1977 and is based in Yilan City, Taiwan.
Key statistics
Avg. volume
366.79K
Market cap
NT$6.44B
P/E Ratio
17.18
Price-to-sales ratio
1.87
Enterprise value
NT$5.65B
Free cash flow yield
7.66%
Debt-to-equity ratio
0.59
Return on equity
10.62%
ROIC
6.84%
Beta
0.07
Dividend yield
2.95%
Last dividend
NT$0.94
Financial overview
Revenue
NT$3.37B
Earnings per share
NT$1.92
Free cash flow
NT$383.72M
Net profit margin
10.19%
Gross margin
43.99%
EBITDA
NT$689.70M
Revenue growth
7.00%
Similar securities
This is not an investment recommendation
Sinphar Pharmaceutical for Indian investors
Sinphar Pharmaceutical is listed on the Taiwan Stock Exchange. It is not currently available to trade on Paasa; the figures on this page are for information, and the tax notes below apply to Indian residents who hold it.
Taxes on Sinphar Pharmaceutical for Indian residents
Trading and limits
- Trading hours
- 9:00 am – 1:30 pm SGT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- Slab rateDividends are taxed at your slab rate in India. Sinphar Pharmaceutical’s current yield is 2.95%.Dividend tax explained
FAQs
Can I buy Sinphar Pharmaceutical on Paasa?
Sinphar Pharmaceutical (1734) has been listed on the Taiwan Stock Exchange since 2002, in the Medical - Pharmaceuticals industry. Sinphar Pharmaceutical is not currently available to trade on Paasa; the figures on this page are for information. Indian residents who hold it through another broker still declare it under the rules below.
How much does one Sinphar Pharmaceutical share cost in rupees?
One Sinphar Pharmaceutical share is NT$31.95 — about ₹96 at a TWD/INR rate of 3.01 on 30 Sep 2026. Both the Sinphar Pharmaceutical price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for investing abroad from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability.
How are gains on Sinphar Pharmaceutical shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the TWD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Sinphar Pharmaceutical price.
Does Sinphar Pharmaceutical pay a dividend, and how is it taxed in India?
Yes. Sinphar Pharmaceutical pays a dividend and the current yield is 2.95%; the last declared dividend was NT$0.94 per share, about ₹2.84. Dividends are taxed at your slab rate in India.
When does TAI trade, in Indian time?
The Taiwan Stock Exchange trades 6:30 am – 11:00 am IST in Indian time.
Do I have to declare Sinphar Pharmaceutical shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. The holding is reported with its cost and its closing value.
Does the rupee rate affect what I make on Sinphar Pharmaceutical?
Yes. Sinphar Pharmaceutical is priced in TWD, so your rupee outcome combines the TWD move with the TWD/INR move between the day you remit and the day you convert back.